I-OMe-Tyrphostin AG 538 is primarily used in research settings as a selective inhibitor of the insulin-like growth factor 1 receptor (IGF-1R). Its application is significant in studying cellular signaling pathways, particularly those involved in cancer biology. By inhibiting IGF-1R, it helps researchers understand the role of this receptor in tumor growth, survival, and metastasis. This compound is also utilized in exploring potential therapeutic strategies for cancers that are driven by IGF-1R signaling, such as certain types of breast, prostate, and lung cancers. Additionally, it aids in investigating the mechanisms of resistance to targeted therapies, providing insights into improving treatment efficacy.